CARGO Therapeutics (CRGX) Projected to Post Earnings on Thursday

CARGO Therapeutics (NASDAQ:CRGX) is expected to announce its earnings results before the market opens on Thursday, March 20th. Analysts expect the company to announce earnings of ($0.95) per share for the quarter.

CARGO Therapeutics Trading Down 2.4 %

Shares of CARGO Therapeutics stock opened at $4.11 on Tuesday. The company’s fifty day simple moving average is $6.94 and its two-hundred day simple moving average is $14.45. The company has a market cap of $189.27 million, a P/E ratio of -0.96 and a beta of 1.65. CARGO Therapeutics has a 12-month low of $3.00 and a 12-month high of $32.79.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on CRGX shares. Jefferies Financial Group downgraded shares of CARGO Therapeutics from a “buy” rating to a “hold” rating and reduced their price objective for the company from $32.00 to $3.00 in a research report on Thursday, January 30th. William Blair downgraded shares of CARGO Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Thursday, January 30th. Truist Financial downgraded shares of CARGO Therapeutics from a “buy” rating to a “hold” rating and reduced their price objective for the company from $32.00 to $7.00 in a research report on Thursday, January 30th. Piper Sandler downgraded shares of CARGO Therapeutics from an “overweight” rating to a “neutral” rating and reduced their target price for the stock from $34.00 to $4.00 in a research report on Thursday, January 30th. Finally, JPMorgan Chase & Co. downgraded shares of CARGO Therapeutics from an “overweight” rating to an “underweight” rating in a research report on Thursday, January 30th. One analyst has rated the stock with a sell rating and six have given a hold rating to the company’s stock. Based on data from MarketBeat.com, CARGO Therapeutics currently has an average rating of “Hold” and an average target price of $15.00.

About CARGO Therapeutics

CARGO Therapeutics, Inc, a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies.